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patients with icterus than without (P ¼ 0.224) and P¼
0.0081) respectively. Total days for disease resolution in pa-
tients with icterus was 32 days compared to 16 days for those
without (p¼0.022). Nine of the patients with icterus received
speciﬁc treatment compared to only one in the anicteric
group. Seven cases were diagnosed with VOD by the Seattle
criteria at a median of day +15 post HSCT, but treatment was
delayed by 1-11 days for lack of hyperbilirubinemia, 2 of
these never developed hyperbilirubinemia; 4 of 7 cases died.
Overall 2 with anicteric and 12 cases with icteric VOD died.
Discussion: The Baltimore criteria appear to bemore stringent
and cases with anicteric VOD do not meet these diagnostic
criteria. This retrospective study describes the features of
anicteric VOD at a single center. Even if the patients met the
Seattle criteria, treatment was delayed for lack of hyper-
bilirubinemia or ﬂow reversal on hepatic ultrasound, neither of
which are required criteria. Patients with anicteric VOD had a
better outcome than those with hyperbilirubinemia, but our
study shows that there can be signiﬁcant morbidity and even
mortality associated with anicteric VOD. There seems to be a
poor understanding and awareness of anicteric VOD as a diag-
nosis.Earlierdisease recognitioncould lead tomorepromptand
aggressive treatment leading to improved outcomes.226
Preservation of Ovarian Function after Hematopoietic
Cell Transplantation (HCT): More Possible Than We
Thought?
Rachel Phelan 1, Elizabeth Mann2, Char Napurski 3,
Todd E. Defor 4, Anna Petryk 5,Weston P.Miller 6, John E.Wagner 7,
Michael R. Verneris 8, Angela R. Smith 9. 1 Pediatric Hematology/
Oncology/Blood and Marrow Transplant, University of
Minnesota, Minneapolis, MN; 2 Pediatrics, University of
Minnesota, Minneapolis, MN; 3 Cancer Survivorship Program,
University of Minnesota, Minneapolis, MN; 4 BMT Research
Program, University of Minnesota, Minneapolis, MN; 5Division
of Pediatric Endocrinology, University of Minnesota,
Minneapolis, MN; 6 Pediatric Blood and Marrow Transplant,
University of Minnesota, Minneapolis, MN; 7 Pediatric Blood and
Marrow Transplantation, University of Minnesota, Minneapolis,
MN; 8 Pediatric Hematology and Oncology, University of
Minnesota Medical Center, Fairview, Minneapolis, MN;
9 Pediatric Hematology/Oncology/Blood and Marrow
Transplantation, University of Minnesota Medical Center,
Fairview, Minneapolis, MN
Background: Gonadal failure is a major long-term health
and quality of life concern in survivors of HCT. While ovarian
dysfunction is nearly universal followingmyeloablative (MA)
conditioning, it is likely variable after reduced-intensity
conditioning (RIC) HCT where there are substantial differ-
ences in intensity. GnRH agonists, such as leuprolide, have
been shown to decrease the rate of ovarian failure in those
receiving conventional chemotherapy, but little is known
about leuprolide’s effectiveness in the HCT population. We
sought to determine the impact of leuprolide on ovarian
function in recipients of MA conditioning and evaluate the
incidence of ovarian failure in women undergoing RIC HCT.
Methods: Post-menarchal females <50 years of age who
were scheduled to undergo HCT were recruited for the study.
Adequate ovarian function, as deﬁned by a baseline FSH level
less than 40 and normal menstrual cycles, was required.
Those undergoing MA HCT were treated with leuprolide
(long-acting 11.25 mg IM once + short-acting 0.2 mg daily for
14 days) prior to conditioning. MA regimens were variable.
Those undergoing RIC HCT were observed with nointervention. RIC regimens generally included cyclophos-
phamide (50 mg/kg), ﬂudarabine (150-200 mg/kg) and TBI
(200-300 cGy). FSHwasmeasured at baseline, day 100,180, 1
year, and 2 years following transplant.
Results: A total of 19 women were included (9 in the inter-
vention armand10observation only). In the intervention arm
(age 17 to 45 years), 6 of the 7 evaluable patients had malig-
nancies and one had an inherited bone marrow failure syn-
drome (IBMFS). The observation arm (age 13 to 45 years)
included 6 patients with aplastic anemia, 1 with a hemoglo-
binopathy,1with ametabolic disorder,1with an IBMFS, and a
single patient with a malignancy. Two patients in the inter-
vention arm were not evaluable (one died 34 days following
HCT and the other was lost to follow-up). There were no
adverse events related to leuprolide therapy. Five out of the 7
intervention patients were heavily pretreated with chemo-
therapy for their malignant conditions prior to HCT. The
incidence of ovarian failure in women undergoing MA trans-
plant who received leuprolidewas 57% (4 out of 7 subjects) at
day +180 compared to historically reported rates of ovarian
failure of >90% after MA transplant. In RIC HCT, the ovarian
failure rate was 20% (2 out of 10 subjects).
Conclusions: Leuprolide is not only safe, but it appears to
have a substantial impact on ovarian function preservation
after MA conditioning. These results were found despite the
majority of these women having received signiﬁcant gona-
dotoxic chemotherapy prior to being referred for HCT. In
addition, early data demonstrate that RIC with cyclophos-
phamide, ﬂudarabine and low-dose TBI is associated with a
low risk of ovarian failure. Further studies are needed to
conﬁrm these exciting ﬁndings.227
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Introduction: The increased survival of hematological pa-
tients has required to widen the care of these patients, with
emphasis in factors related to quality of life and late mor-
tality. Among them, osteoporosis (OP) is a fundamental
problem. Patients undergoing hematopoietic cell trans-
plantation (HCT) are at great risk of OP, mainly due to pro-
longed exposure to chemotherapy, immunosuppresants and
the hypogonadism frequently associated to these treatments.
Despite this, there is lack of strong evidence on this matter
and HCT guidelines are not clear on this problem.
Objectives: To evaluate parameters related to bone health in
patients undergoing HCT. To measure the frequency and
severity of the alterations in this group of patients.
Patients and Methods: Observational and retrospective
analysis of patients undergoing HCTat the Catholic University
Hematology-Oncology Department. All patients undergoing
HCT were recommended to have determination of 25-OH
vitamin D, PTHi, Calcium, Phosphorus and bone densitometry
(DXA). We included all patients with the evaluation before
HCT (preHCT) and 1 year after HCT (postHCT). Statistical
analysis was performed by SPSS v.21 software.
Results: We obtained data from 20 patients preHCT and 22
patients postHCT.Main diagnosiswere acutemyeloid leukemia
(n¼13; 32%), multiple myeloma (n¼11; 26%), acute lympho-
blastic leukemia (n¼9; 21%) and Hodgkin’s Lymphoma (n¼5;
12%). Mean age was 40 years (range: 17-67) and 67% were
males. In the preHCTgroup, themedian25-OHvitaminD levels
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tients were in the insufﬁciency range levels (<30 ng/ml). Me-
dianPTHi levelswere62,6pg/ml (range:24,4-223,7pg/ml), and
46% of the patients had secondary hyperparathyroidism. In the
postHCTgroup,median25-OHvitaminD levelswere11,4ng/ml
(range: 4-29,4 ng/ml) and 100%had insuﬁciency levels.Median
PTHi levelswere 68pg/ml (range: 37,4-135,8pg/ml), and56%of
the patients had secondary hyperparathyroidism. 12 patients
had DXA before HCT and 3 (25%) of them had DXA lumbar Z
score less than -2.0. In 19 patients postHCT, 4 (21%) had
decreasedDXAZscore< 2.0.Nodifference couldbeestablished
between autologous or allogeneic HCT in any measurement.
Only the presence of chronic graft vs host disease (GVHD) was
associated with higher PTH levels by ANOVA test. None of the
other variables were associated with acute or chronic GVHD.
Conclusions: HCT patients represent a high-risk group of
developing severe vitamin D deﬁciency, secondary hyper-
parathyroidism and decreased DXA levels. These data are a
warning that this population of patients requires early inter-
vention toprevent long-termcomplications. This report is the
initial evaluation for the development and treatment of bone
health in a prospective matter in HCT patients in our center.228
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Leukemia relapses occurring in donor cells, so-called donor cell
leukemias (DCL) after allogeneic hematopoietic stem cell
transplantationhave been reported in several cases and still are
considered as rare diseases. Cytogenetic analysis, ﬂow cytom-
etryandmolecular testinghavebeenused to conﬁrm this event
in the cases so far reported. The incidence of this condition is
largelyunknown,aswellas the resultsof its treatment.Wehave
prospectively searched for DCL in a 12-year period, in a single
institution. In a group of 106 consecutive patients allografted
because of leukemia we have identiﬁed 7 cases of DCL; six of
themwere allografted because of relapsed acute lymphoblastic
leukemia (ALL) and one because of paroxysmal nocturnal he-
moglobinuria/aplastic anemia; these ﬁgures suggest that the
real incidence of DCL has been underestimated in previous
studies. All the patients were allografted from HLA-identical
siblings, employing a reduced-intensity conditioning regimen.
The cases appeared with median of 10 months after the allo-
graft; the number of blast cells when the leukemic activity
ensued was above 50% in all cases, whereas the chimerism
studies revealedmore than 90% cells of donor origin. The origin
of the leukemia cellswas shownbymicrosatellites andwith sex
mismatch. Six patients with lymphoblastic DCL were treated
prospectively with a pediatric-inspired combined chemo-
therapy schedule designed for “de novo” ALL patients. A com-
plete responsewas obtained in 3/6 patientswith lymphoblastic
DCL, these patients being alive in a complete remission at 11,12
and 98 months after the diagnosis of DCL. The long-term DCL
survivors remain full chimeras and did not need a second
transplant. It is concluded that the prevalence of DCL may behigher if it is prospectively looked for, and that acceptable
therapeutic results are obtained if patients are treated as “do
novo” leukemias employing combined chemotherapy.229
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Background: Quality of life (QOL) is an important consid-
eration in the counseling, implementation, and post
treatment management of arduous treatments for life-
threatening conditions, such as allogeneic hematopoietic cell
transplantation (allo-HCT).
Material and Methods: QOL was analyzed in leukemia pa-
tients who underwent allo-HCT using reduced intensity
conditioning (RIC) on an outpatient basis at either the Centro
de Hematología y Medicina Interna de Puebla of the Clínica
Ruiz or the Hematology Service of the Internal Medicine
Department of the Hospital “Dr. José Eleuterio González” of
the Universidad Autónoma de Nuevo León, and who had
survived above 12 months after the allograft, who could be
approached, who were in a continued complete remission-
with or without graft versus host disease and who were
willing to respond to the questionnaire. Thirty-ﬁve patients
fulﬁlling these requirements were included, and a sex and
age-matched group of 35 reference subjects was also studied.
Results: Allografted patients were found to have a slightly
better mental component summary than the reference sub-
jects (53.23 versus 48.66 points, p ¼ 0.01), whereas the
physical component summary did not show a difference
(54.53 versus 52.05 points, p ¼ 0.59). Most of the differences
between allografted individuals and reference subjects con-
trols were not signiﬁcant.
Conclusions: These data suggest that allografted individuals
employing our RIC regimen, enjoy a health-related quality of
life similar to that of reference subjects, adding, another
advantage of this method of conducting stem cell allograft-
ing. However, more work needs to be done to elucidate the
impact of RIC on QOL post-allo-HCT.230
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